AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRVO
  4. [8-K] CervoMed Inc. Reports Material Event

[8-K] CervoMed Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Airbnb, Inc. (ABNB) Form 4 key points

  • CTO Aristotle N. Balogh sold 600 Class A shares on 07/24/2025 at $139.39 per share under a Rule 10b5-1 trading plan adopted 02/27/2025.
  • Estimated proceeds: roughly $83.6 k.
  • Balogh now directly owns 209,777.141 Class A shares.
  • No derivative security transactions were reported.

The disposition represents only ~0.29 % of the executive鈥檚 reported holdings and does not alter his role as Chief Technology Officer. Because the trade was pre-scheduled, it is generally considered routine liquidity rather than a directional signal about Airbnb鈥檚 fundamentals.

Punti chiave del Modulo 4 di Airbnb, Inc. (ABNB)

  • Il CTO Aristotle N. Balogh ha venduto 600 azioni di Classe A il 24/07/2025 a 139,39 $ per azione, nell'ambito di un piano di trading Rule 10b5-1 adottato il 27/02/2025.
  • Proventi stimati: circa 83,6 mila $.
  • Balogh detiene ora direttamente 209.777,141 azioni di Classe A.
  • Non sono state segnalate transazioni su strumenti derivati.

La vendita rappresenta solo circa lo 0,29% delle partecipazioni dichiarate dell'esecutivo e non modifica il suo ruolo di Chief Technology Officer. Poich茅 l'operazione era programmata in anticipo, 猫 generalmente considerata una liquidit脿 di routine e non un segnale sull'andamento fondamentale di Airbnb.

Puntos clave del Formulario 4 de Airbnb, Inc. (ABNB)

  • El CTO Aristotle N. Balogh vendi贸 600 acciones Clase A el 24/07/2025 a 139,39 $ por acci贸n bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 27/02/2025.
  • Ingresos estimados: aproximadamente 83,6 mil $.
  • Balogh posee ahora directamente 209.777,141 acciones Clase A.
  • No se reportaron transacciones con valores derivados.

La disposici贸n representa solo aproximadamente el 0,29 % de las participaciones reportadas por el ejecutivo y no altera su rol como Director de Tecnolog铆a. Debido a que la operaci贸n fue programada con anticipaci贸n, generalmente se considera una liquidez rutinaria y no una se帽al direccional sobre los fundamentos de Airbnb.

Airbnb, Inc. (ABNB) Form 4 欤检殧 雮挫毄

  • CTO 鞎勲Μ鞀ろ啝韰旊爤鞀� N. 氚滊攴鸽姅 2025雲� 7鞗� 24鞚检棎 600欤� 韥措灅鞀� A 欤检嫕鞚� 欤茧嫻 139.39雼煬鞐� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 韺愲Г頄堨姷雼堧嫟(2025雲� 2鞗� 27鞚� 毂勴儩).
  • 於旍爼 靾橃澋: 鞎� 8毵� 3,600雼煬.
  • 氚滊攴鸽姅 順勳灛 歆侅爲 209,777.141欤� 韥措灅鞀� A 欤检嫕鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
  • 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

鞚措矆 毵る弰電� 瓴届榿歆勳澊 氤搓碃頃� 氤挫湢 歆�攵勳潣 鞎� 0.29%鞐� 攵堦臣頃橂┌, CTO搿滌劀鞚� 鞐暊鞐愲姅 氤�頃澊 鞐嗢姷雼堧嫟. 瓯半灅臧� 靷爠鞐� 鞓堨暯霅� 瓴冹澊氙�搿� 鞚茧皹鞝侅溂搿� Airbnb鞚� 旮半掣鞝� 臧�旃橃棎 雽�頃� 氚╉枼靹� 鞁犿樃氤措嫟電� 鞚检儊鞝侅澑 鞙犽彊靹� 頇曤炒搿� 臧勳＜霅╇媹雼�.

Points cl茅s du Formulaire 4 d'Airbnb, Inc. (ABNB)

  • Le CTO Aristotle N. Balogh a vendu 600 actions de classe A le 24/07/2025 au prix de 139,39 $ par action dans le cadre d'un plan de trading Rule 10b5-1 adopt茅 le 27/02/2025.
  • Produit estim茅 : environ 83,6 k$.
  • Balogh d茅tient d茅sormais directement 209 777,141 actions de classe A.
  • Aucune transaction sur des titres d茅riv茅s n'a 茅t茅 signal茅e.

Cette cession repr茅sente seulement environ 0,29 % des avoirs d茅clar茅s de l'ex茅cutif et ne modifie pas son r么le de Chief Technology Officer. 脡tant donn茅 que la transaction 茅tait pr茅programm茅e, elle est g茅n茅ralement consid茅r茅e comme une liquidit茅 de routine plut么t qu'un signal directionnel sur les fondamentaux d'Airbnb.

Wichtige Punkte zum Formular 4 von Airbnb, Inc. (ABNB)

  • CTO Aristotle N. Balogh verkaufte am 24.07.2025 600 Class-A-Aktien zum Preis von 139,39 $ pro Aktie im Rahmen eines Rule 10b5-1 Handelsplans, der am 27.02.2025 angenommen wurde.
  • Gesch盲tzte Erl枚se: ca. 83,6 Tsd. $.
  • Balogh besitzt nun direkt 209.777,141 Class-A-Aktien.
  • Keine Transaktionen mit Derivaten wurden gemeldet.

Der Verkauf stellt nur etwa 0,29 % der gemeldeten Best盲nde des Gesch盲ftsf眉hrers dar und 盲ndert nichts an seiner Position als Chief Technology Officer. Da der Handel vorab geplant war, wird er allgemein als routinem盲脽ige Liquidit盲t betrachtet und nicht als richtungsweisendes Signal f眉r die Fundamentaldaten von Airbnb.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, pre-planned sale; neutral signal for investors.

The 600-share sale equates to under 0.3 % of Balogh鈥檚 stake, yielding about $84 k and leaving a sizable 210 k-share position. Given the Rule 10b5-1 framework, the transaction appears routine and carries limited informational value regarding near-term performance or insider sentiment. I view the filing as non-impactful to ABNB鈥檚 investment thesis.

TL;DR: Governance-compliant trade; no red flags detected.

Use of a 10b5-1 plan and prompt Form 4 submission indicate strong compliance with insider-trading rules. The modest size relative to total ownership and absence of derivative activity reduce concerns about potential negative signaling. From a governance standpoint, the event is routine and unlikely to influence shareholder perspectives.

Punti chiave del Modulo 4 di Airbnb, Inc. (ABNB)

  • Il CTO Aristotle N. Balogh ha venduto 600 azioni di Classe A il 24/07/2025 a 139,39 $ per azione, nell'ambito di un piano di trading Rule 10b5-1 adottato il 27/02/2025.
  • Proventi stimati: circa 83,6 mila $.
  • Balogh detiene ora direttamente 209.777,141 azioni di Classe A.
  • Non sono state segnalate transazioni su strumenti derivati.

La vendita rappresenta solo circa lo 0,29% delle partecipazioni dichiarate dell'esecutivo e non modifica il suo ruolo di Chief Technology Officer. Poich茅 l'operazione era programmata in anticipo, 猫 generalmente considerata una liquidit脿 di routine e non un segnale sull'andamento fondamentale di Airbnb.

Puntos clave del Formulario 4 de Airbnb, Inc. (ABNB)

  • El CTO Aristotle N. Balogh vendi贸 600 acciones Clase A el 24/07/2025 a 139,39 $ por acci贸n bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 27/02/2025.
  • Ingresos estimados: aproximadamente 83,6 mil $.
  • Balogh posee ahora directamente 209.777,141 acciones Clase A.
  • No se reportaron transacciones con valores derivados.

La disposici贸n representa solo aproximadamente el 0,29 % de las participaciones reportadas por el ejecutivo y no altera su rol como Director de Tecnolog铆a. Debido a que la operaci贸n fue programada con anticipaci贸n, generalmente se considera una liquidez rutinaria y no una se帽al direccional sobre los fundamentos de Airbnb.

Airbnb, Inc. (ABNB) Form 4 欤检殧 雮挫毄

  • CTO 鞎勲Μ鞀ろ啝韰旊爤鞀� N. 氚滊攴鸽姅 2025雲� 7鞗� 24鞚检棎 600欤� 韥措灅鞀� A 欤检嫕鞚� 欤茧嫻 139.39雼煬鞐� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 韺愲Г頄堨姷雼堧嫟(2025雲� 2鞗� 27鞚� 毂勴儩).
  • 於旍爼 靾橃澋: 鞎� 8毵� 3,600雼煬.
  • 氚滊攴鸽姅 順勳灛 歆侅爲 209,777.141欤� 韥措灅鞀� A 欤检嫕鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
  • 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

鞚措矆 毵る弰電� 瓴届榿歆勳澊 氤搓碃頃� 氤挫湢 歆�攵勳潣 鞎� 0.29%鞐� 攵堦臣頃橂┌, CTO搿滌劀鞚� 鞐暊鞐愲姅 氤�頃澊 鞐嗢姷雼堧嫟. 瓯半灅臧� 靷爠鞐� 鞓堨暯霅� 瓴冹澊氙�搿� 鞚茧皹鞝侅溂搿� Airbnb鞚� 旮半掣鞝� 臧�旃橃棎 雽�頃� 氚╉枼靹� 鞁犿樃氤措嫟電� 鞚检儊鞝侅澑 鞙犽彊靹� 頇曤炒搿� 臧勳＜霅╇媹雼�.

Points cl茅s du Formulaire 4 d'Airbnb, Inc. (ABNB)

  • Le CTO Aristotle N. Balogh a vendu 600 actions de classe A le 24/07/2025 au prix de 139,39 $ par action dans le cadre d'un plan de trading Rule 10b5-1 adopt茅 le 27/02/2025.
  • Produit estim茅 : environ 83,6 k$.
  • Balogh d茅tient d茅sormais directement 209 777,141 actions de classe A.
  • Aucune transaction sur des titres d茅riv茅s n'a 茅t茅 signal茅e.

Cette cession repr茅sente seulement environ 0,29 % des avoirs d茅clar茅s de l'ex茅cutif et ne modifie pas son r么le de Chief Technology Officer. 脡tant donn茅 que la transaction 茅tait pr茅programm茅e, elle est g茅n茅ralement consid茅r茅e comme une liquidit茅 de routine plut么t qu'un signal directionnel sur les fondamentaux d'Airbnb.

Wichtige Punkte zum Formular 4 von Airbnb, Inc. (ABNB)

  • CTO Aristotle N. Balogh verkaufte am 24.07.2025 600 Class-A-Aktien zum Preis von 139,39 $ pro Aktie im Rahmen eines Rule 10b5-1 Handelsplans, der am 27.02.2025 angenommen wurde.
  • Gesch盲tzte Erl枚se: ca. 83,6 Tsd. $.
  • Balogh besitzt nun direkt 209.777,141 Class-A-Aktien.
  • Keine Transaktionen mit Derivaten wurden gemeldet.

Der Verkauf stellt nur etwa 0,29 % der gemeldeten Best盲nde des Gesch盲ftsf眉hrers dar und 盲ndert nichts an seiner Position als Chief Technology Officer. Da der Handel vorab geplant war, wird er allgemein als routinem盲脽ige Liquidit盲t betrachtet und nicht als richtungsweisendes Signal f眉r die Fundamentaldaten von Airbnb.

false 0001053691 0001053691 2025-07-28 2025-07-28
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
July 28, 2025
Date of Report (Date of earliest event reported)
 
 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
001-37942
30-0645032
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
   
20 Park Plaza, Suite 424
Boston, Massachusetts
02116
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
___________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.001 par value
  
CRVO
  
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 7.01         Regulation FD Disclosure
 
Press Release
 
On July 28, 2025, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing 32-week data from the extension phase (the “Extension Phase”) of the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (“RewinD-LB”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
 
Presentation
 
Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including Week 32 results from the Extension Phase of RewinD-LB, has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.
 
The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.
 
--
 
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 8.01         Other Events
 
The information set forth in the first paragraph and the information under the headings, “New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial,” “New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase,” “Previously Presented 16-Week Extension Phase Data,” and “Old and New Capsules Have Similar Overall Safety and Tolerability Profile During Extension Phase,” of the Company’s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
 
Item 9.01                  Financial Statements and Exhibits
 
(d)         Exhibits
 
The following exhibit relating to Item 7.01 is furnished and not filed:
 
Exhibit No.
Description
   
99.1
Press Release, issued July 28, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: July 28, 2025
CervoMed Inc.
  
       
 
By:
/s/ William Elder
  
 
Name:
William Elder
  
 
Title:
Chief Financial Officer & General Counsel
  
 
 

Source:

FAQ

How many Airbnb (ABNB) shares did CTO Aristotle Balogh sell?

He sold 600 Class A shares.

What price did the ABNB insider receive per share?

The reported sale price was $139.39 per share.

What is Balogh鈥檚 remaining ABNB share ownership after the sale?

He now directly holds 209,777.141 Class A shares.

Was the transaction part of a pre-planned trading program?

Yes. The sale was conducted under a Rule 10b5-1 plan adopted on 02/27/2025.

Does this Form 4 filing indicate any derivative security activity?

No. No derivative securities were reported in the filing.
Stock CRVO logo
CervoMed

NASDAQ:CRVO

CRVO Rankings

#6722 Ranked by Market Cap
N/A Ranked by Dividends

CRVO Latest News

Jul 28, 2025
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod鈥檚 Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Jul 24, 2025
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
Jul 8, 2025
CervoMed Announces Late-Breaking Presentations at Alzheimer鈥檚 Association庐 International Congress 2025
Jun 10, 2025
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
May 12, 2025
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

CRVO Latest SEC Filings

Jun 25, 2025
[8-K] CervoMed Inc. Reports Material Event
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] CervoMed Inc. Insider Trading Activity

CRVO Stock Data

78.15M
5.79M
33.38%
17.22%
10.96%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON